Vera Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vera Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Vera Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 28.8 %, a 25.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 28.8 -10.1 -25.9% Jun 30, 2024
Q1 2024 34.2 -0.28 -0.81% Mar 31, 2024
Q4 2023 44.4 +12.9 +41% Dec 31, 2023
Q3 2023 42.7 +20.1 +88.6% Sep 30, 2023
Q2 2023 38.8 +19.9 +105% Jun 30, 2023
Q1 2023 34.5 +19.9 +136% Mar 31, 2023
Q4 2022 31.5 +11.4 +56.7% Dec 31, 2022
Q3 2022 22.6 +441 Sep 30, 2022
Q2 2022 18.9 Jun 30, 2022
Q1 2022 14.6 Mar 31, 2022
Q4 2021 20.1 Dec 31, 2021
Q3 2021 -419 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.